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Abstract Portal ¢broblasts (PF) are a newly isolated popula-
tion of ¢brogenic cells in the liver postulated to play a signi¢-
cant role in early biliary ¢brosis. Because transforming growth
factor-L (TGF)-L is a key growth factor in ¢brosis, we charac-
terized the response of PF to TGF-L. We demonstrate that PF
produce signi¢cant amounts of TGF-L2 and, unlike activated
hepatic stellate cells (HSC), express all three TGF-L receptors
and are growth inhibited by TGF-L1 and TGF-L2. Fibroblast
growth factor (FGF)-2, but not platelet derived growth factor
(PDGF), causes PF proliferation. These data suggest a mecha-
nism whereby HSC eclipse PF as the dominant myo¢broblast
population in biliary ¢brosis.
, 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Portal ¢broblasts (PF) are a newly identi¢ed and isolated
population of ¢brogenic cells found in the portal region of the
liver [1^8]. Their periportal localization as well as rapid pro-
liferation and acquisition of K-smooth muscle actin expression
immediately after bile duct ligation suggest that they are dis-
tinct from hepatic stellate cells (HSC). They express procolla-
gen-1 mRNA and are postulated to be the early mediators of
hepatic ¢brosis after biliary injury, with HSC comprising a
later cellular response [6^9].
Transforming growth factor-L (TGF-L) is one of the most
important mediators of ¢brosis in the liver. Multiple studies
have demonstrated that TGF-L is highly expressed in ¢brotic
regions, that overexpression of TGF-L in animal models re-
sults in ¢brosis, and that TGF-L antagonists can prevent ex-
perimentally induced ¢brosis [10^14]. Although TGF-L1 is the
major TGF-L isoform in the liver, TGF-L2 is of special inter-
est because one report suggests that it is the primary TGF-L
isoform expressed by proliferating bile duct epithelia in the
¢brotic liver [15]. This raises the possibility that TGF-L pro-
duced by biliary epithelial cells, in particular TGF-L2, might
play an important role in biliary ¢brosis and might have im-
portant e¡ects on the adjacent population of PF.
We sought to characterize the TGF-L response of PF in
culture, looking in particular at growth inhibition and pro-
duction of extracellular matrix material in response to both
TGF-L1 and TGF-L2. We also examined similarities and dif-
ferences between PF and in vitro activated and passaged
HSC, which have a well-characterized response to TGF-L
[16,17].
2. Materials and methods
2.1. Materials
Cell culture media, fetal calf serum (FCS), and antibiotics were
obtained from Gibco BRL (Carlsbad, CA, USA). Chemicals and en-
zymes for cell isolation were obtained from Sigma (St. Louis, MO,
USA), with the exception of pronase, which was from Calbiochem
(San Diego, CA, USA). 100 mm pore mesh was obtained from Selfar
America, Inc. (Kansas City, MO, USA). Growth factors were ob-
tained from RpD Systems (Minneapolis, MN, USA). TGF-L receptor
kinase inhibitor NPC-34016 was a generous gift from David Liu
(Scios, Inc., Sunnyvale, CA, USA). Radiochemicals were obtained
from New England Nuclear (Boston, MA, USA). Antibodies against
TGF-L receptors were obtained from Santa Cruz (V22 and L21 for
the type I TGF-L receptor (TLRI) and the type II TGF-L receptor
(TLRII), respectively; Santa Cruz, CA, USA) and RpD Systems, Inc.
(betaglycan); the antibody against ¢bronectin was from Invitrogen
(Carlsbad, CA, USA).
2.2. Cell isolation and culture
Primary rat PF were isolated as described [1]. Brie£y, rat non-pa-
renchymal cell (NPC) fractions were obtained by collagenase and
pronase digestion of rat livers followed by serial mesh ¢ltration to
mechanically disrupt cells. NPC were plated in Dulbecco’s modi¢ed
Eagle’s medium (DMEM)/F-12 medium containing 2% penicillin^
streptomycin, 3% FCS, 0.3% gentamicin, and 0.1% fungizone. Cells
were observed at 96 h, at which point all cells remaining were PF. For
all experiments reported here, cells were used at passages 2^4.
HSC were isolated as described [17], grown on tissue culture plastic,
and used at passages 24.
2.3. Receptor a⁄nity labeling and immunoprecipitation
PF and HSC in culture were labeled with 250 pM [125I]TGF-L1, as
described [18]. Cells were lysed and equal fractions were immunopre-
cipitated with antibodies against the type I receptor, the type II re-
ceptor, or betaglycan. Immunoprecipitants were separated by sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) and
visualized by autoradiography.
2.4. Matrix assays
Fibronectin secretion was measured as described [17]. For measure-
ment of plasminogen activator inhibitor (PAI)-1 deposition, cells were
treated with 100 pM TGF-L1 or -L2 or with 0.5 WM TGF-L receptor
kinase inhibitor NPC-34016 for 2 h in DMEM lacking cysteine, me-
thionine, and glutamine (ICN, Irvine, CA, USA). 35S-Express labeling
mix was added to 33 WCi/ml, and cells were labeled for 3 h. Plates
were rinsed with phosphate-bu¡ered saline (PBS) one time, with 10
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mM Tris pH 8.0/0.5% deoxycholic acid/1 mM phenylmethylsulfame-
thoxazole three times, then with 2 mM Tris pH 8.0 two times. After a
¢nal rinse with PBS, the remaining matrix was scraped into reducing
SDS sample bu¡er, then boiled and separated by SDS^PAGE. PAI-1
appears as a characteristic 47 kDa band. Autoradiographs were
scanned and quantitated with ImageJ software (NIH).
2.5. [3H]thymidine incorporation
[3H]thymidine uptake was measured as described [17]. In short, cells
were placed in DMEM/0.3% fetal bovine serum with growth factors
for 4 h. [3H]thymidine was added to 2 WCi/ml for an additional 22 h,
at which point cells were rinsed, lysed in 2 M NaOH, and counted.
TGF-L was used at 10 and 100 pM as noted, ¢broblast growth factor
(FGF)-2 at 1.2 nM, and platelet derived growth factor (PDGF)-BB at
0.1 Wg/ml. Some cells were treated with 0.5 WM TLRI kinase inhibitor
(solubilized in dimethyl sulfoxide (DMSO)) or with the equivalent
volume of DMSO. Signi¢cance was determined by paired Student’s
t-test.
2.6. Quantitation of TGF-L release
Release of biologically active TGF-L1 and TGF-L2 was quantitated
using commercially available immunoassays according to the manu-
facturer’s instructions (TGF-L1 Emax and TGF-L2 Emax, Promega,
Madison, WI, USA). TGF-L1 and TGF-L2 immunoassays were per-
formed in parallel. PF were grown in six-well culture plates to near
con£uence. For a positive control, HepG2 human hepatoblastoma cells
were grown under identical conditions. Cells were counted, then in-
cubated overnight with TGF-L coat antibody at 4‡C. Non-speci¢c
binding was inhibited with a blocking bu¡er for 35 min at 37‡C. Cells
were treated with secondary antibody for 2 h at room temperature
followed by tertiary horseradish peroxidase (HRP)-conjugated anti-
body for 2 h at room temperature. After adding HRP reagent for
15 min at room temperature, color change was detected using a mul-
ti-well plate absorbance spectrophotometer (PowerWare 340, Bio-Tek
Instruments, Winooski, VT, USA) at 450 nm. Results were calibrated
to a standard curve of known either TGF-L1 or TGF-L2 concentra-
tions done at eight dilutions (two data points per concentration) with
correlations (r2 values) s 0.955 for each immunoassay. For the TGF-
L1 immunoassay, there is less than or equal to 3% cross-reactivity
with TGF-L2 or -L3, and for the TGF-L2 immunoassay there is less
than or equal to 3% cross-reactivity with TGF-L1 or -L3.
3. Results
3.1. PF express all three TGF-L receptors
TGF-L signals through the sequential action of two serine-
threonine kinase cell surface receptors, TLRI and TLRII. Sig-
naling by the TGF-L isoform TGF-L2, however, is greatly
enhanced in some cells by the presence of betaglycan, a pro-
teoglycan accessory receptor that acts by enhancing the a⁄n-
ity of TLRI and TLRII for the ligand [19]. Although TGF-L1
is the major TGF-L isoform expressed in the liver, TGF-L2 is
produced at high levels in the proliferating bile ducts seen in
biliary ¢brosis [15]. We therefore sought to determine whether
PF, which are adjacent to the biliary epithelial cells, express
betaglycan and can potentially respond to TGF-L2. Cells were
a⁄nity labeled with [125I]TGF-L1 and cell lysates were immu-
noprecipitated with antibodies against all three TGF-L recep-
tors. As seen in Fig. 1 (left panel), all three receptors are
expressed on the surface of PF. This is in contrast to HSC,
which express betaglycan in vitro only when quiescent or in an
intermediate state, but not when activated (M.D.A. GacQa and
R.G. Wells, unpublished results) and passaged (Fig. 1, right
panel).
3.2. PF produce minimal matrix in response to TGF-L
In order to determine whether PF respond to TGF-L, and
in particular whether they produce matrix in response to
TGF-L, we measured the expression of ¢bronectin and PAI-
1 with and without TGF-L treatment. Cells show a modest
(less than 2-fold) but signi¢cant increase in expression of both
matrix-active components when treated with TGF-L1 or -L2
(Fig. 2), similar to the response we have observed with acti-
vated HSC in vitro (Fig. 2 and [17]). Additionally, cells were
treated with a TLRI kinase inhibitor to determine whether
baseline matrix production resulted from autocrine TGF-L
production. Although there is a small but signi¢cant decrease
in matrix production after inhibitor treatment, suggesting that
autocrine TGF-L is responsible for some of the baseline ma-
trix production, the lack of complete inhibition suggests that
multiple factors are responsible for PF matrix production. As
a control, Rat1 ¢broblasts were treated with TGF-L1 and
TGF-L2 in parallel, and demonstrated a 1.6^1.8-fold increase
in ¢bronectin secretion and a 13^14-fold increase in PAI-1
deposition (data not shown). Interestingly, these cells showed
minimal background production of either matrix component,
unlike PF and activated HSC. Northern blotting for collagen
K1(I) showed no change in mRNA levels with TGF-L or in-
hibitor treatment (data not shown).
3.3. PF are growth inhibited by TGF-L but are stimulated by
FGF-2
The e¡ect of TGF-L on growth of PF was determined by
measuring incorporation of [3H]thymidine. Both TGF-L1 and
-L2 cause a reproducible inhibition in [3H]thymidine incorpo-
ration, even when used at 10 pM (Fig. 3). Similar results were
seen with TGF-L3 (data not shown). Interestingly, treatment
with FGF-2 stimulates growth, although PDGF has no e¡ect.
Treatment of cells with the TLRI kinase inhibitor increased
growth, suggesting that autocrine TGF-L production causes a
tonic growth inhibition. PF behaved di¡erently than HSC at
Fig. 1. PF express all three TGF-L receptors. Left: PF in culture
were a⁄nity labeled with [125I]TGF-L1. Cells were lysed, and lysates
immunoprecipitated with antibodies against the type I (I) and type
II (II) receptors and betaglycan (BG). All three cell surface recep-
tors are present on the surface of these cells. Right: In vitro acti-
vated HSC at the same passage number were similarly treated, but
demonstrate labeling primarily of the type II receptor.
Table 1
TGF-L isoform production (pg/105 cells)
Isoform PF HepG2
TGF-L1 52.6R 4.1 (n=24) 237.1R 26.2 (n=16)
TGF-L2 3341R 1340 (n=17) 328.2R 80.9 (n=15)
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similar passage number; [3H]thymidine incorporation by HSC
was strongly enhanced by PDGF, but the other growth fac-
tors and the TLRI kinase inhibitor had no e¡ect.
3.4. Autocrine production of TGF-L1 and TGF-L2 by PF
Production of biologically active TGF-L1 and TGF-L2 was
measured using a commercially available immunoassay (Table
1). PF secreted signi¢cant amounts of TGF-L1 and, surpris-
ingly, even larger amounts (64 times as much) TGF-L2.
HepG2 human hepatoblastoma cells, used as a control, pro-
duced similar amounts of TGF-L1 and TGF-L2, as has been
reported in the literature [20] ; our HepG2 data are also quan-
titatively similar to previously reported values [20,21].
4. Discussion
PF are one of several potentially ¢brogenic cell types iden-
ti¢ed in the liver. PF are of special interest because they are
restricted to the portal region, particularly around intrahe-
patic bile ducts, and thus may be important in the biliary
¢brosis that occurs with such diseases as primary biliary cir-
rhosis, primary sclerosing cholangitis, and cystic ¢brosis [9].
There is now increasing evidence that there are several pop-
ulations of myo¢broblasts in the diseased liver in addition to
those derived from HSC [2,4,5,8,22]. PF may be a population
of cells, akin to HSC, that di¡erentiate into myo¢broblasts. It
has been suggested that PF transdi¡erentiation occurs early in
biliary ¢brosis, and that HSC activate and migrate into the
periportal area at a later point [8,9]. Although the stimuli for
transdi¡erentiation of either PF or HSC into myo¢broblasts
are not well understood, they are clearly di¡erent. One group
has demonstrated that PDGF stimulates K-smooth muscle
actin expression in a PF-like ¢broblast population isolated
from bile duct preparations [5]. HSC do not express the
PDGF receptor L-subunit until activated, indicating that
PDGF cannot be an early stimulus for HSC transdi¡erentia-
tion [23].
Our data demonstrate additional di¡erences between PF
and culture-activated HSC at a similar passage number. PF
are growth inhibited by TGF-L, whereas activated HSC are
not, and PF, as demonstrated in Fig. 1, express all three TGF-
L receptors on the cell surface, while activated HSC express
minimal cell surface betaglycan (Figs. 1 and 3 and M.D.A.
GacQa and R.G. Wells, unpublished results). Activated HSC
proliferate in response to PDGF, while PF respond to FGF-2
(Fig. 3 and [24]). Both cell types, however, demonstrate a less
than 2-fold increased matrix production in response to TGF-
L, suggesting that TGF-L is not the major direct ¢brogenic
Fig. 2. TGF-L does not induce matrix production by PF. PF were treated with growth factors and a TLRI kinase inhibitor as indicated and as-
sayed for deposition of ¢bronectin (A) and PAI-1 (B). Duplicates represent independent plates of cells. Autoradiographs of proteins were quan-
titated and the results shown graphically. Values are meanRS.D. for two independent experiments with four to ¢ve replicates total. *P6 0.05
compared with (3) (for TGF-L1 and -L2 treatment), or compared with DMSO alone (for inhibitor treatment). C: In vitro activated HSC at
the same passage number were treated similarly.
FEBS 28063 3-2-04
R.G. Wells et al./FEBS Letters 559 (2004) 107^110 109
stimulus [16,17,25]. Activated HSC and PF both have a high
baseline level of matrix production compared with control
cells, suggesting that they are ¢brogenic even in the absence
of exogenous stimuli.
We have shown that PF, unlike activated HSC, express
betaglycan and are growth inhibited by TGF-L2. This implies
that activated HSC have a growth advantage in biliary ¢bro-
sis, particularly in the periportal region, where bile duct epi-
thelial cells in proliferating bile ducts and, as we have shown,
PF themselves, produce TGF-L2 [15]. The data suggest that
autocrine production of large amounts of TGF-L2 by PF and
TGF-L1 by PF and activated HSC is also likely to growth
suppress PF preferentially, while production of PDGF by
HSC and biliary epithelial cells facilitates HSC but not PF
proliferation [26]. Taken collectively, our ¢ndings are consis-
tent with the hypothesis that biliary ¢brosis results from the
sequential transdi¡erentiation of PF and HSC, and suggest
mechanisms whereby HSC become the dominant myo¢bro-
blast population.
The interactions between HSC and PF in biliary ¢brosis are
not well understood. Autocrine production of TGF-L by PF
could play a direct role in activation of HSC; alternatively,
the production of even small amounts of matrix by PF in
response to TGF-L could represent an important change in
the liver milieu that leads to HSC activation. The ability to
isolate PF now makes it possible to study their interactions
with HSC directly, as well as the role of growth factors such
as FGF-2, PDGF, and TGF-L2.
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Fig. 3. TGF-L1 and -L2 inhibit proliferation of PF. PF were labeled
with [3H]thymidine for 26 h in the presence of growth factors and
inhibitors. A, left panel: Cells were treated with TGF-L1 and -L2 as
well as FGF-2 and PDGF. A, right panel: Cells were treated with
the TLRI kinase inhibitor NPC-34016 (solubilized in DMSO) or
with equivalent amounts of DMSO alone. B: HSC at a similar pas-
sage number were treated similarly. Note that the y axes di¡er in
each graph, and that mitogenic e¡ects of various treatments are
lower for PF than for passaged HSC. Values are meanRS.D. for
six replicates, and are representative of ¢ndings in three separate ex-
periments. *P6 0.05; **P6 0.001; compared with (3) or DMSO
controls.
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